1. Market Research
  2. > Pharmaceutical
  3. > Drug Development Market Trends
3D Printed Drugs Market by Spritam (U.S. and Rest of World) and Other Drugs Potential Market - Global Opportunity Analysis and Industry Forecast, 2017-2030

3D Printed Drugs Market by Spritam (U.S. and Rest of World) and Other Drugs Potential Market - Global Opportunity Analysis and Industry Forecast, 2017-2030

  • November 2017
  • 125 pages
  • ID: 5228659
  • Format: PDF
  • By Allied Market Research

Summary

Table of Contents

3D Printed Drugs Market by Spritam (U.S. and Rest of World) and Other Drugs Potential Market by Scenario (Rapid Growth Scenario, Moderate Growth Scenario, and Low Growth Scenario) - Global Opportunity Analysis and Industry Forecast, 2017-2030

Spritam is the only 3D printed drug which has received FDA approval. This drug was first available in the market in 2016, and can be used to treat epilepsy. The potential market for other 3D printed drugs (moderate growth scenario) is estimated to be $278 million in 2020, and would reach $522 million by 2030, growing at a CAGR of 6.5% from 2020 to 2030. 3D printed drugs are developed by 3D printing technology to treat patients and children affected with dysphagia. These drugs are highly porous in nature and disintegrate rapidly, which eliminate the need to directly swallow the intact high-dose medicine.

The growth of the 3D printed drugs market is driven by upsurge in demand of instantaneous soluble drugs, rise in geriatric population, and high adoption of 3D printing technology. In addition, rapid technological advancements, increase in awareness about the 3D printing, and improvement in healthcare infrastructure fuel the market growth. However, factors such as adverse effects related to these drugs, lack of government regulations for these drugs, and use of 3D printing to develop illegal drugs are expected to restrain the market growth. Conversely, introduction of 3D printed drugs by various key vendors in developing nations and increase in healthcare investment in emerging nations are expected to provide lucrative opportunities for the market growth in the near future.

The market is segmented on the basis of Spritam, scenario, and geography. For Spritam, market is categorized on the basis of geography into U.S. and rest of North America. On the basis of scenario, the market is categorized into low growth scenario, moderate growth scenario, and rapid growth scenario. Geographically, it is analyzed across North America (U.S. and rest of North America), Europe (UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global 3D printed drugs market with current trends and future estimations to elucidate the investment pockets.
Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
The report offers a quantitative analysis to assist the stakeholders to capitalize on prevailing market opportunities.
Extensive analysis of different segments facilitates to determine various products available in the market.
Key players are profiled and their strategies are analyzed thoroughly to predict the competitive market outlook.

SPRITAM MARKET, BY GEOGRAPHY
U.S.
Rest of World

OTHER DRUGS POTENTIAL MARKET, BY SCENARIO
Low Growth Scenario
Moderate Growth Scenario
Rapid Growth Scenario

OTHER DRUGS POTENTIAL MARKET, BY REGION
North America
U.S.
Rest of North America
Europe
UK
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT
Aprecia Pharmaceuticals
GlaxoSmithKline Plc.
Hewlett Packard Caribe, BV, LLC
3D Printer Drug Machine
FabRx Ltd.

LIST OF ORGANIZATIONS PROFILED IN THE REPORT
UCL School of Pharmacy
University of Glasgow
University College London
The University of Nottingham
National University of Singapore

LIST OF OTHER ORGANIZATIONS IN THE VALUE CHAIN (These players are not profiled in the report, but can be included on client request.)
University of Michigan
Åbo Akademi University
University of Sheffield

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Retrovirus Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019

Retrovirus Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019

  • $ 4000
  • December 2019

Retrovirus Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019SummaryMedical Devices sector report, “Retrovirus Rapid Tests & Point of Care (POC) - Medical Devices Pipeline ...

Endometriosis - Pipeline Review, H2 2019

Endometriosis - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Endometriosis - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis - Pipeline Review, H2 2019, provides an overview of the Endometriosis (Women’s ...

Celiac Disease - Pipeline Review, H2 2019

Celiac Disease - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Celiac Disease - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Celiac Disease - Pipeline Review, H2 2019, provides an overview of the Celiac Disease (G ...


ref:plp2017

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on